Rhumbline Advisers Cidara Therapeutics, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$1.87 - $2.7 $52,057 - $75,162	-27,838 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$2.06 - $3.01 $9,270 - $13,544	-4,500 Reduced 13.92%	27,838 $74,000
Q4 2020 Feb 10, 2021	BUY	$1.99 - $3.25 $17,464 - $28,522	8,776 Added 37.25%	32,338 $65,000
Q3 2020 Nov 12, 2020	SELL	$2.85 - $4.1 $12,497 - $17,978	-4,385 Reduced 15.69%	23,562 $67,000
Q2 2020 Aug 13, 2020	BUY	$2.39 - $4.0 $66,793 - $111,788	27,947 New	27,947 $103,000

22.1M

2.7K

100

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $837M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.